<VariationArchive RecordType="classified" VariationID="11353" VariationName="NM_000061.3(BTK):c.141+3_141+4del" VariationType="Deletion" Accession="VCV000011353" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-04-25" DateCreated="2018-11-03" MostRecentSubmission="2018-11-03">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="26392" VariationID="11353">
      <GeneList>
        <Gene Symbol="BTK" FullName="Bruton tyrosine kinase" GeneID="695" HGNC_ID="HGNC:1133" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xq22.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101349450" stop="101390796" display_start="101349450" display_stop="101390796" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100604434" stop="100641211" display_start="100604434" display_stop="100641211" Strand="-" />
          </Location>
          <OMIM>300300</OMIM>
          <Haploinsufficiency last_evaluated="2021-03-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BTK">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-03-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BTK">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000061.3(BTK):c.141+3_141+4del</Name>
      <CanonicalSPDI>NC_000023.11:101375139:TT:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq22.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101375140" stop="101375141" display_start="101375140" display_stop="101375141" variantLength="2" positionVCF="101375139" referenceAlleleVCF="CTT" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100630128" stop="100630129" display_start="100630128" display_stop="100630129" variantLength="2" positionVCF="100630127" referenceAlleleVCF="CTT" alternateAlleleVCF="C" />
      </Location>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009616.1" sequenceAccession="NG_009616" sequenceVersion="1" change="g.16084_16085del">
            <Expression>NG_009616.1:g.16084_16085del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001287344.2" sequenceAccession="NM_001287344" sequenceVersion="2" change="c.243+3_243+4del">
            <Expression>NM_001287344.2:c.243+3_243+4del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000061.3" sequenceAccession="NM_000061" sequenceVersion="3" change="c.141+3_141+4del" MANESelect="true">
            <Expression>NM_000061.3:c.141+3_141+4del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001287345.2" sequenceAccession="NM_001287345" sequenceVersion="2" change="c.141+3_141+4del">
            <Expression>NM_001287345.2:c.141+3_141+4del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.100630128_100630129del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.100630128_100630129del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.101375140_101375141del" Assembly="GRCh38">
            <Expression>NC_000023.11:g.101375140_101375141del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_128" sequenceAccession="LRG_128">
            <Expression>LRG_128:g.16084_16085del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_128t1" sequenceAccession="LRG_128t1">
            <Expression>LRG_128t1:c.141+3_141+4del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="BTK_000331" DB="BTK @ LOVD" />
        <XRef ID="CA341085" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="300300.0012" DB="OMIM" />
        <XRef Type="rs" ID="864321661" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000061.3(BTK):c.141+3_141+4del AND X-linked agammaglobulinemia" Accession="RCV000012106" Version="12">
        <ClassifiedConditionList TraitSetID="3110">
          <ClassifiedCondition DB="MedGen" ID="C0221026">X-linked agammaglobulinemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1994-10-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="1994-10-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2018-11-03" MostRecentSubmission="2018-11-03">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">7880320</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3110" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="39" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">X-linked agammaglobulinemia</ElementValue>
                <XRef ID="X-linked+agammaglobulinemia/7543" DB="Genetic Alliance" />
                <XRef ID="65880007" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Agammaglobulinemia, Bruton tyrosine kinase</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Agammaglobulinemia, BTK</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">BTK-deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">IMMUNODEFICIENCY 1</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Bruton-type agammaglobulinemia</ElementValue>
                <XRef ID="MONDO:0010421" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Bruton's agammaglobulinemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">AGAMMAGLOBULINEMIA, X-LINKED, TYPE 1</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">XLA</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">AGMX1</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">IMD1</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="1033" />
                <XRef ID="1033" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">X-linked agammaglobulinemia (XLA) is characterized by recurrent bacterial infections in affected males in the first two years of life. Recurrent otitis is the most common infection prior to diagnosis. Conjunctivitis, sinopulmonary infections, diarrhea, and skin infections are also frequently seen. Approximately 60% of individuals with XLA are recognized as having immunodeficiency when they develop a severe, life-threatening infection such as pneumonia, empyema, meningitis, sepsis, cellulitis, or septic arthritis. S pneumoniae and H influenzae are the most common organisms found prior to diagnosis and may continue to cause sinusitis and otitis after diagnosis and the initiation of gammaglobulin substitution therapy. Severe, difficult-to-treat enteroviral infections (often manifest as dermatomyositis or chronic meningoencephalitis) can be prevented by this treatment. The prognosis for individuals with XLA has improved markedly in the last 25 years as a result of earlier diagnosis, the development of preparations of gammaglobulin that allow normal concentrations of serum IgG to be achieved, and more liberal use of antibiotics.</Attribute>
                <XRef ID="NBK1453" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301626</ID>
                <ID Source="BookShelf">NBK1453</ID>
              </Citation>
              <XRef ID="229717" DB="Orphanet" />
              <XRef ID="47" DB="Orphanet" />
              <XRef ID="C0221026" DB="MedGen" />
              <XRef ID="MONDO:0010421" DB="MONDO" />
              <XRef Type="MIM" ID="300755" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="32340" SubmissionDate="2018-10-30" DateLastUpdated="2018-11-03" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="300300.0012_AGAMMAGLOBULINEMIA, X-LINKED" title="BTK, 2-BP DEL, IVS2DS, +3AA_AGAMMAGLOBULINEMIA, X-LINKED" />
        <ClinVarAccession Accession="SCV000032340" DateUpdated="2018-11-03" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1994-10-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a patient with X-linked agammaglobulinemia (XLA; 300755), Hagemann et al. (1994) identified a 2-bp deletion at the 5-prime end of intron 2 of the BTK gene. Two adenines were deleted from positions +3 and +4 of the consensus sequence GTAAGT at the donor splice site. Although the deletion does not break the GT/AG boundary rule, the resulting donor splice site does not match the consensus sequence, and the mutation would most likely result in exon 2 skipping. This would remove the 5-prime end of the coding sequence, including the translation start site and the PH domain.</Attribute>
              <Citation>
                <ID Source="PubMed">7880320</ID>
              </Citation>
              <XRef DB="OMIM" ID="300755" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BTK" />
          </GeneList>
          <Name>BTK, 2-BP DEL, IVS2DS, +3AA</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">2-BP DEL, IVS2DS, +3AA</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="300300.0012" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">AGAMMAGLOBULINEMIA, X-LINKED</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="32340" TraitType="Disease" MappingType="Name" MappingValue="AGAMMAGLOBULINEMIA, X-LINKED" MappingRef="Preferred">
        <MedGen CUI="C0221026" Name="X-linked agammaglobulinemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

